WWM
NVO

Willingdon Wealth Management’s Novo Nordisk NVO Stock Holding History

Willingdon Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.77M Buy
158,486
+9,084
+6% +$270K 1.2% 30
2019
Q4 		$4.32M Buy
149,402
+7,996
+6% +$221K 0.89% 37
2019
Q3 		$3.65M Buy
141,406
+4,184
+3% +$106K 0.8% 41
2019
Q2 		$3.5M Buy
137,222
+7,204
+6% +$178K 0.81% 41
2019
Q1 		$3.4M Buy
130,018
+2,564
+2% +$63K 0.83% 45
2018
Q4 		$2.94M Buy
127,454
+11,552
+10% +$257K 0.85% 42
2018
Q3 		$2.73M Buy
115,902
+2,668
+2% +$65.1K 0.75% 58
2018
Q2 		$2.61M Buy
113,234
+5,186
+5% +$123K 0.8% 56
2018
Q1 		$2.66M Buy
108,048
+11,526
+12% +$303K 0.84% 48
2017
Q4 		$2.59M Buy
96,522
+2,618
+3% +$66.6K 0.85% 51
2017
Q3 		$2.26M Buy
93,904
+3,272
+4% +$73.9K 0.82% 52
2017
Q2 		$1.94M Buy
90,632
+2,650
+3% +$53.5K 0.77% 63
2017
Q1 		$1.51M Buy
87,982
+4,442
+5% +$77.3K 0.61% 67
2016
Q4 		$1.5M Buy
83,540
+4,714
+6% +$85.5K 0.71% 62
2016
Q3 		$1.64M Buy
78,826
+33,110
+72% +$821K 0.83% 54
2016
Q2 		$1.23M Buy
45,716
+964
+2% +$26.4K 0.63% 71
2016
Q1 		$1.21M Sell
44,752
-45,148
-50% -$1.21M 0.74% 64
2015
Q4 		$2.61M Buy
89,900
+4,724
+6% +$131K 2.39% 8
2015
Q3 		$2.31M Sell
85,176
-720
-0.8% -$20.4K 2.75% 5
2015
Q2 		$2.35M Sell
85,896
-10,622
-11% -$299K 2.25% 6
2015
Q1 		$2.58M Sell
96,518
-27,216
-22% -$627K 2.14% 10
2014
Q4 		$2.62M Buy
123,734
+96
+0.1% +$2.14K 1.65% 19
2014
Q3 		$2.94M Buy
123,638
+2,884
+2% +$66.4K 1.94% 15
2014
Q2 		$2.79M Sell
120,754
-45,716
-27% -$1.01M 1.93% 14
2014
Q1 		$3.8M Sell
166,470
-1,850
-1% -$39.4K 2.67% 3
2013
Q4 		$3.11M Buy
+168,320
New +$2.93M 2.44% 9

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Willingdon Wealth Management's NVO Position: Q1 2020 in Review

Willingdon Wealth Management increased its Novo Nordisk (NVO) stake by 6.1% in Q1 2020, buying an estimated $270K and bringing the position to 158,486 shares worth $4.77M. The position accounts for 1.2% of the portfolio, ranked #30.

Willingdon Wealth Management first reported a position in NVO in Q4 2013 and has held it in 26 quarters since. 644 funds tracked by Wall St. Rank hold NVO as of Q1 2020.

  • Willingdon Wealth Management held 158,486 shares of Novo Nordisk worth $4.77M as of Q1 2020.
  • Willingdon Wealth Management bought 9,084 Novo Nordisk shares in Q1 2020, an estimated $270K.
  • Novo Nordisk made up 1.2% of Willingdon Wealth Management's portfolio in Q1 2020, its #30 holding.
  • Willingdon Wealth Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 26 quarters since.
  • 644 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2020.

Based on Willingdon Wealth Management's 13F filing for Q1 2020, filed 21 Apr 2020.